TY - JOUR
T1 - Development of next generation hemagglutinin-based broadly protective influenza virus vaccines
AU - Nachbagauer, Raffael
AU - Palese, Peter
N1 - Funding Information:
Work in the Palese laboratory is supported by NIAID grant U19 AI109946 , the Bill and Melinda Gates Foundation , PATH and GlaxoSmithKline .
Funding Information:
Work in the Palese laboratory is supported by NIAID grant U19 AI109946, the Bill and Melinda Gates Foundation, PATH and GlaxoSmithKline.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/8
Y1 - 2018/8
N2 - Influenza viruses are a severe threat to human health and current vaccines do not provide sufficient protection. The highly variable nature of influenza viruses has made the production of efficacious vaccines a challenge. In recent years, a multitude of novel, broadly reactive influenza virus vaccination approaches have been described. What has long seemed impossible could now become reality in the near future — a new generation of influenza virus vaccines that provides long-lasting and broad protection against seasonal as well as potentially pandemic influenza virus strains. This review will discuss new hemagglutinin-based vaccines and their current stage of development.
AB - Influenza viruses are a severe threat to human health and current vaccines do not provide sufficient protection. The highly variable nature of influenza viruses has made the production of efficacious vaccines a challenge. In recent years, a multitude of novel, broadly reactive influenza virus vaccination approaches have been described. What has long seemed impossible could now become reality in the near future — a new generation of influenza virus vaccines that provides long-lasting and broad protection against seasonal as well as potentially pandemic influenza virus strains. This review will discuss new hemagglutinin-based vaccines and their current stage of development.
UR - http://www.scopus.com/inward/record.url?scp=85045581646&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2018.04.001
DO - 10.1016/j.coi.2018.04.001
M3 - Review article
C2 - 29680576
AN - SCOPUS:85045581646
SN - 0952-7915
VL - 53
SP - 51
EP - 57
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -